KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

CAMBRIDGE, Mass. & SALISBURY, England -- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pendopharm, a division of Pharmascience Inc., the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE).

KalVista grants Pendopharm rights to commercialize sebetralstat for HAE - BioTuesdays

KalVista Pharmaceuticals (NASDAQ: KALV) has announced that it has entered into a licensing agreement with closely held Pendopharm to manage the regulatory approval process and commercialization of sebetralstat, an investigational oral on-demand treatment for hereditary angioedema (HAE). The financial terms of the agreement were not disclosed. In a statement, Ben Palleiko, CEO of KalVista, commented, “We look forward to collaborating with Pendoph…